Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress and reported second quarter 2023 financial results.
Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress and reported second quarter 2023 financial results.